Skip to Content
scroll

Neuren Pharmaceuticals Ltd (NEU)

ASX.NEU $21.01

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

LEARN MORE

NEU $21.01

20 MINUTE DELAYED

TODAY

-0.38 %

1 YEAR RETURN

0.00%

VOLUME

254,663

DIV YIELD

0%

PE RATIO

17.06

52 WEEK RANGE

10.02

25.95

ANALYSIS

i

SHARE PRICE ACTIVITY
Last (Price)

21.01

Change

-0.08 (-0.38)

Bid / Ask

20.94 - 21.05

Volume

254,663

Turnover

5,319,997

Open

21.10

Day Range

20.45 - 21.11

VWAP

20.89

Prev Close

21.09

Last Trade

20/05 4:10pm (AEST)

i

KEY INFORMATION
Sector

Shares Issued

NTA/Share

0.00

Last Dividend

0.00

Dividend Ex Date

0

Dividend Pay Date

29 MAR 2006

i

BROKER CALLS

current

Mean

1.83

Target Price

0.00

BUY

i

CURRENT ()
Revenue

231.93

EBITDA

205.16

Profit

157.08

Earnings Per Share (EPS)

0

Dividend Per Share (DPS)

0

Yield %

0.00

Market Cap

0

Price to Earnings Ratio (P/E)

17.06

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

152.15

EBITDA

117.77

Profit

91.29

Earnings Per Share (EPS)

0.72

Dividend Per Share (DPS)

0.00

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation (BUY)

1.83
OPINION
ACTION
image description

Business Summary

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company that is engaged in developing drugs for neurological disorders. The Company’s lead drug compound, Trofinetide, is in a Phase III clinical trial in the United States for Rett syndrome and has completed a Phase II clinical trial in Fragile X syndrome. Its both programs have each received Fast Track designation by the United States Food and Drug Administration (FDA) and Orphan Drug designation in both the United States and the European Union. The Company has granted a license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America, while retaining all rights outside North America. The Company is preparing to initiate Phase II trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome.

image description

Only available to Members

Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing. Click here
Back to top